View Older Stories View More Recent Stories

Dec 4, 2017 07:08AM BioLineRx (BLRX) Announces Positive Overall Survival Results From L-T Follow-up of Phase 2a Trial in r/r AML
Dec 4, 2017 07:00AM BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
Nov 21, 2017 07:00AM BioLineRx Reports Third Quarter 2017 Financial Results
Nov 20, 2017 07:00AM BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
Nov 16, 2017 07:00AM BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York
Nov 9, 2017 07:00AM BioLineRx to Report Third Quarter 2017 Results on November 21, 2017
Nov 2, 2017 07:21AM BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
Oct 18, 2017 07:05AM BioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
Oct 18, 2017 07:00AM BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
Sep 26, 2017 07:05AM BioLineRx (BLRX) Reports Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
Sep 26, 2017 07:00AM BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
Sep 7, 2017 08:00AM BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 21, 2017 07:04AM BioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD
Aug 21, 2017 07:00AM BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
Aug 8, 2017 07:00AM BioLineRx Reports Second Quarter 2017 Financial Results
Aug 2, 2017 07:00AM BioLineRx to Report Second Quarter 2017 Results on August 8, 2017
Jul 26, 2017 07:00AM BioLineRx Announces Additional Investment From BVF Partners L.P.
Jul 10, 2017 07:10AM BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
Jul 10, 2017 07:00AM BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
Jun 1, 2017 07:04AM BioLineRx (BLRX) Announces Submission of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
Jun 1, 2017 07:00AM BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
May 25, 2017 07:00AM BioLineRx Reports First Quarter 2017 Financial Results
May 22, 2017 07:03AM BioLineRx (BLRX) Files BL-8040 Phase 1b Trial Regulatory Submission in Combo with atezolizumab in AML
May 22, 2017 07:00AM BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
May 16, 2017 07:00AM BioLineRx to Report First Quarter 2017 Results on May 25, 2017
May 3, 2017 07:04AM BioLineRx (BLRX) Initiate Phase 3 Study with BL-8040 Following Successful Meeting with FDA
May 3, 2017 07:00AM BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
Apr 5, 2017 11:22AM BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
Mar 31, 2017 08:27AM BioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS
Mar 31, 2017 08:25AM BioLineRx Prices $25 Million Underwritten Public Offering
Mar 30, 2017 04:18PM BioLineRx (BLRX) to Offer ADSs
Mar 30, 2017 04:01PM BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
Mar 27, 2017 09:15AM BioLineRx (BLRX) Says AGI-134 to be Featured at AACR
Mar 27, 2017 09:13AM BioLineRx's AGI-134 to be Presented at AACR 2017
Mar 23, 2017 08:00AM BioLineRx Reports Year End 2016 Financial Results
Mar 23, 2017 07:04AM BioLineRx (BLRX) Acquires Agalimmune
Mar 23, 2017 07:00AM BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
Mar 20, 2017 07:17AM BioLineRx (BLRX) Reports Partial Results Data from Open-Label Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Mar 20, 2017 07:00AM BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
Mar 16, 2017 10:00AM BioLineRx to Report Annual 2016 Results on March 23, 2017
Feb 7, 2017 07:00AM BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
Jan 17, 2017 07:01AM BioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040
Jan 17, 2017 07:00AM BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Jan 4, 2017 07:00AM BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco
Dec 5, 2016 07:08AM BioLineRx (BLRX) Presents Positive Phase 2a Correlative and Mechanism-of-Action Data for BL-8040 at ASH
Dec 5, 2016 07:00AM BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Nov 22, 2016 08:00AM BioLineRx Reports Third Quarter 2016 Financial Results
Nov 21, 2016 07:06AM BioLineRx (BLRX) Enters In-Licensing Agreement for Anti-Inflammatory DES Treatment
Nov 21, 2016 07:00AM BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
Nov 15, 2016 07:00AM BioLineRx to Report Third Quarter Results on November 22, 2016
View More Recent Stories View Older Stories